Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8703526 | 1.00 | F2RL3 (0.42) | F2RL3TP53CYP3A4ALOX15TSHR | |
| SCHEMBL8702640 | 0.92 | TP53 (0.49) | TP53CYP3A4ALOX15TSHRMAPK1 | |
| SCHEMBL8702646 | 0.92 | TP53 (0.49) | TP53CYP3A4ALOX15TSHRMAPK1 | |
| SCHEMBL8702684 | 0.92 | TP53 (0.49) | TP53CYP3A4ALOX15TSHRMAPK1 | |
| SCHEMBL8706554 | 0.87 | KLK7 (0.45) | F2RL3TSHRALOX5APFEN1 | |
| SCHEMBL8706557 | 0.87 | KLK7 (0.45) | F2RL3TSHRALOX5APFEN1 | |
| SCHEMBL8703528 | 0.83 | TP53 (0.56) | TP53CYP3A4ALOX15TSHRMAPK1 | |
| SCHEMBL8702049 | 0.83 | CHRNB4 (0.55) | TP53CYP3A4ALOX15TSHRMAPK1 | |
| SCHEMBL9413621 | 0.82 | ALOX5AP (0.44) | F2RL3TSHRMAPK1ALOX5APABCB1 | |
| SCHEMBL9413620 | 0.82 | ALOX5AP (0.44) | F2RL3TSHRMAPK1ALOX5APABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |